MozzettiS,Ferlini C,Concolino P,et al.Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel esistance in ovarian cancer patients[J].Clin Canceres,2005,11(1):298-303.
Ohishi Y,Oda Y,Kurihara S,et al. Nuclear localization of E-cadherin but not beta-catenin in human ovarian granulosa cell tumours and normal ovarian follicles and ovarian stroma[J]. Histopathology,2011,58(3):423-432.
Guoyang Sun,Junxia Wu,Jiansheng Wu,et al. Caveolin-1,E-cadherin and β-catenin in Gastric Carcinoma,Precancerous Tissues and Chronic Non-atrophic Gastritis[J].Chinese Journal of Cancer Research,2012,24(1):23-28.
[8]
Xu XY,Shi Y,Zhang PP,et al.E-cadherin mediates adhesion and endocytosis of Aspergillus fumigatus blastospores in human epithelial cells[J].Chin Med J,2012,125(4):617-621.
[9]
Kam Y,Quaranta V. Cadherin-bound beta-catenin feeds into the Wnt path-way upon adherens junctions dissociation:evidence for an intersection between beta-catenin pools[J]. PLoS One,2009,4(2):e4580.
[10]
Freimann S,Ben-Ami I,Hirsh L,et al. Drug development for ovarian hyper-stimulation and anti-cancer treatment:blocking of gonadotropin signaling for epiregulin and amphiregulin biosynthesis[J].Biochemical Pharmacology,2004,68(6):989-996.
[11]
Wadia PR,Mahale SD,Nandedkar TD. Effect of the human follicle-stimulating hormone-binding inhibitor and its N-terminal fragment on follicle-stimulating hormone-induced progesterone secretion by granulosa cells in vitro[J]. Journal of Biosciences,2007,32(6):1185-1194.
[12]
Bose CK. Follicle stimulating hormone receptor(FSHR)antagonist and epithelial ovarian cancer(EOC)[J]. Journal of Experimental Therapeutics & Oncology,2007,6(3):201-204.
